Alebund Pharmaceuticals (Jiangsu) Limited operates as a biopharmaceutical company that develops therapies for kidney diseases and their complications in China and Hong Kong. Its products include AP301, a phosphate binder; AP306, a sodium-dependent phosphate transport protein inhibitor; one early-clinical-stage product candidate AP303; and four preclinical product candidates, including AP308, AP304, AP305, and AP307. Alebund Pharmaceuticals (Jiangsu) Limited was founded in 2018 and is headquartered in Yangzhou, China.